Combined Therapy of Alpha-1-Antitrypsin and Temporal T-Cell Depletion for Preventing Graft Rejection

Eli Lewis

Combined Therapy of Alpha-1-Antitrypsin and Temporal T-Cell Depletion for Preventing Graft Rejection

Eli Lewis (Inventor)

Department of Clinical Biochemistry and Pharmacology

Research output: Patent

Abstract

A method of preventing or treating xenotransplant rejection in a subject in need thereof is disclosed. The method comprises administering a therapeutically effective amount of alpha-1-antitrypsin (AAT) in combination with a therapeutically effective amount of an anti-CD8 antibody or an antigen binding fragment thereof.

Original language	English
Patent number	US10086070B2
State	Published - 1 Oct 2018

Cite this

@misc{4db93372b0994e8282e6cf0c2dea77d0,

title = "Combined Therapy of Alpha-1-Antitrypsin and Temporal T-Cell Depletion for Preventing Graft Rejection",

abstract = "A method of preventing or treating xenotransplant rejection in a subject in need thereof is disclosed. The method comprises administering a therapeutically effective amount of alpha-1-antitrypsin (AAT) in combination with a therapeutically effective amount of an anti-CD8 antibody or an antigen binding fragment thereof.",

author = "Eli Lewis",

note = "US Patent 10,086,070; US10086070B2",

year = "2018",

month = oct,

day = "1",

language = "English",

publisher = "Google Patents",

type = "Patent",

}

TY - PAT

T1 - Combined Therapy of Alpha-1-Antitrypsin and Temporal T-Cell Depletion for Preventing Graft Rejection

AU - Lewis, Eli

N1 - US Patent 10,086,070

PY - 2018/10/1

Y1 - 2018/10/1

N2 - A method of preventing or treating xenotransplant rejection in a subject in need thereof is disclosed. The method comprises administering a therapeutically effective amount of alpha-1-antitrypsin (AAT) in combination with a therapeutically effective amount of an anti-CD8 antibody or an antigen binding fragment thereof.

AB - A method of preventing or treating xenotransplant rejection in a subject in need thereof is disclosed. The method comprises administering a therapeutically effective amount of alpha-1-antitrypsin (AAT) in combination with a therapeutically effective amount of an anti-CD8 antibody or an antigen binding fragment thereof.

M3 - Patent

M1 - US10086070B2

PB - Google Patents

ER -

Combined Therapy of Alpha-1-Antitrypsin and Temporal T-Cell Depletion for Preventing Graft Rejection

Abstract

Fingerprint

Cite this